Cargando…

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study

Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scotto, Riccardo, Buonomo, Antonio Riccardo, Iuliano, Antonio, Foggia, Maria, Sardanelli, Alessia, Villari, Riccardo, Pinchera, Biagio, Gentile, Ivan, Federico II COVID-Team
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/ https://www.ncbi.nlm.nih.gov/pubmed/36851078 http://dx.doi.org/10.3390/vaccines11020200

Ejemplares similares

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

Update on the Management of Surgical Site Infections
por: Pinchera, Biagio, et al.
Publicado: (2022)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19
por: Scotto, Riccardo, et al.
Publicado: (2022)

Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
por: Scotto, Riccardo, et al.
Publicado: (2022)

SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience
por: Pinchera, Biagio, et al.
Publicado: (2022)

Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study
por: Viceconte, Giulio, et al.
Publicado: (2023)

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience
por: Gentile, Ivan, et al.
Publicado: (2021)

mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study
por: Pinchera, Biagio, et al.
Publicado: (2022)

Diabetes and COVID-19: The potential role of mTOR
por: Pinchera, B., et al.
Publicado: (2022)

Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19
por: Pinchera, Biagio, et al.
Publicado: (2023)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

Current evidence on the management of hepatitis B in pregnancy
por: Maraolo, Alberto Enrico, et al.
Publicado: (2018)

Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?
por: Nardelli, Carmela, et al.
Publicado: (2021)

COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy)
por: Gentile, Ivan, et al.
Publicado: (2022)

Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves
por: Cattaneo, Letizia, et al.
Publicado: (2023)

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients
por: Biagio, Pinchera, et al.
Publicado: (2022)

Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia
por: Scotto, Riccardo, et al.
Publicado: (2021)

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2020)

Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
por: Gentile, Ivan, et al.
Publicado: (2021)

Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma
por: Capoluongo, Ettore, et al.
Publicado: (2021)

Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2021)

Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens
por: Zappulo, Emanuela, et al.
Publicado: (2019)

The role of curcumin in liver diseases
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2018)

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
por: Hirai, Jun, et al.
Publicado: (2023)

Cytometric analysis of patients with COVID-19: what is changed in the second wave?
por: Scalia, Giulia, et al.
Publicado: (2021)

Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection
por: Scalia, Giulia, et al.
Publicado: (2022)

Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
por: Cacciapuoti, Sara, et al.
Publicado: (2020)

544. Outpatient Remdesivir Use at a Stand Alone Children's Hospital
por: Rodriguez, Brittany, et al.
Publicado: (2023)

Local Outbreak of COVID-19 in Shunyi District Attributed to an Asymptomatic Carrier with a History of Stay in Indonesia — Beijing Municipality, China, December 23, 2020
por: COVID-19 Epidemiology Investigation Team,, et al.
Publicado: (2021)

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

474. Real-World Experience of the Comparative Effectiveness and Safety of Remdesivir and Combination Therapy (Remdesivir and Monoclonal Antibodies) in Immunosuppressed Patients with Mild to Moderate COVID-19: A Retrospective Single-center Study in a Community Setting
por: Hirai, Jun, et al.
Publicado: (2023)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient
por: Vargas, Maria, et al.
Publicado: (2019)

Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2019)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Remdesivir increases mtDNA copy number causing mild alterations to oxidative phosphorylation
por: DeFoor, Nicole, et al.
Publicado: (2023)

Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
por: Cross, Robert W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ar5bq0kqmsuslc6l2udjotctn6